智通财经APP获悉，在诺和诺德(NVO.US)终止与远程医疗公司Hims & Hers Health合作后，摩根士丹利发布研报给予Hims & Hers ...

智通财经APP获悉，在诺和诺德 (NVO.US)终止与远程医疗公司Hims & Hers Health合作后，摩根士丹利发布研报给予Hims & Hers Health (HIMS.US)“与大盘持平”评级，最新目标价40美元。

Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

Law Offices of Howard G. Smith reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Hims & Hers Health, Inc ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

摩根士丹利 分析师在研报中指出，Hims & Hers Health面临的核心问题在于，若 诺和诺德 对其发起诉讼，该公司能否继续提供复合式GLP-1药物疗法。

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...

Senate To Begin Marathon Vote Series On Trump's "Big, Beautiful Bill" As GOP Eyes July 4 Deadline The Senate is set to kick off what's expected to be a marathon session Monday, after the chamber ...

Weight Watchers is Novo Nordisk's latest partnersip.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Hims & Hers losses, you mayCLICK HERE or copy and paste the following link into your browser: ...

诺和诺德反应激烈，一方面是因为一旦出现不合规问题，药企将会受到严厉的处罚、付出惨重的代价。跨国药企因为合规问题被罚数十亿美元的情况并不少见。这种情况下，如果合作伙伴合规风险不可控，确实会令药企抓狂。